Breast Cancer Articles

Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients
Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.
Progress for TNBC Seen Across Treatment Modalities
Although chemotherapy remains the mainstay of treatment for patients with triple-negative breast cancer, promising developments are unfolding on several fronts, including new ways of using existing therapies and the exploration of immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway.
The FDA approved the PARP inhibitor olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer. 
Novel Treatments Emerging in HER2+ Breast Cancer Pipeline
Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.
Analysis Confirms Safety of Olaparib in Breast Cancer
An analysis of the phase III OlympiAD study showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.
FDA Grants Ribociclib Breakthrough Designation for HR+/HER2- Premenopausal Breast Cancer
The FDA has granted ribociclib a breakthrough therapy designation for use in combination with tamoxifen or an aromatase inhibitor as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
Controversies and Clinical Trials for DCIS: Margins and Active Surveillance
The management of ductal carcinoma in situ is one of the most controversial areas in breast cancer management.
The combination of lapatinib, trastuzumab, and an aromatase inhibitor (AI) reduced the risk for death or progression by 38% in women with HER2+/HR+ metastatic breast cancer compared with those treated with a targeted agent plus AI.
Long-Term Data Published for Neratinib in HER2+ Breast Cancer
Extended adjuvant therapy with neratinib significantly reduced the proportion of clinically relevant breast cancer relapses without increasing the risk of long-term toxicity.
Hamilton Highlights Treatment Landscape of HER2+ Breast Cancer
Erika P. Hamilton, MD, discusses recent FDA approvals in the treatment paradigm of HER2-positive breast cancer.
Publication Bottom Border
Border Publication